Establishment of a COVID-19 convalescent plasma bank from COVID-19 Recovered donors containing high titers of anti-SARS-CoV-2 antibody titers
We are seeking recovered COVID-19 patients to donate plasma in an emergency clinical trial. Your antibodies will be used to help treat severely ill patients battling the disease in Western New York and may help lessen their symptoms. To complete the online screening form, visit http://www.buffalo.edu/ctsi/covidplasma
Certain criteria are required for you to donate your plasma. We will call you to review your screening form and ask more questions about the course of your illness. If you are eligible, we will refer you to the local collection site to schedule a donation appointment. Donation will involve one or more blood draws. The project is part of the National COVID-19 Convalescent Plasma Project, which the Food and Drug Administration has approved as an Emergency Investigational New Drug (EIND).
1. To isolate convalescent plasma from donors who recovered from COVID-19 infection. We will invite adult blood donor with history of confirmed COVID-19 infection to participate in this study by donating one unit of blood. Plasma from these blood donation presumably will contain high titers of anti-SARS-CoV-1 neutralizing antibodies. In anticipation for the use of COVID-19 convalescent plasma with high anti-SARS-CoV-2 antibody titers, we propose to evaluate donor???s blood samples for the presence of blood borne pathogens including HIV, Hepatitis B, Hepatitis C, syphilis, and SARS-CoV-2.
2. Evaluate anti-SARS-CoV-2 antibody titers among healthy individuals who recovered from COVID-19 infection. We propose to screen convalescent plasma sample for the presence of anti-SARS-CoV-2 capsid proteins by a rapid test. Plasma samples that test positive will undergo ELISA testing to measure specific anti-SARS-CoV-2 S protein antibody titers (e.g., synthetic capsid antigen of Genescript ELISA kit) on serial serum samples obtained from these individuals.
3. To evaluate donor of anti-SARS-CoV-2 convalescent sera for SARS-CoV-2 neutralization experiments in vitro using pulmonary-derived tissue culture cells. Sera obtained from individuals that recover from COVID-19 infection will be evaluated for the ability to neutralize SARS-CoV-2 based on plaque assay on bronchial epithelial cell lines. Inhibition assay will be conducted with purified ACE-2 protein or with SARS-CoV-2 purified capsid protein to evaluate specificity of binding. (This aim will be considered at a later stage).
Adults ages 18+
Have tested positive for COVID-19 or were exhibiting symptoms of COVID-19 without an initial test
Are now at least 28 days without symptoms
Due to COVID-19, new enrollment in research studies will be greatly limited.
If you are interested in a study, there may be a longer waiting period to receive a response to your inquiry.
View the guidance for research participants for additional information.
Let us know how the study team can reach you.
If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email email@example.com and someone will assist you.